NAD+ IV Therapy (NAD+ Drip): What It Is and What to Check

This guide explains what NAD+ IV therapy is, how it differs from an injection, what UK clinics publish about doses and session lengths and what the evidence shows.

We do not provide, sell or arrange treatment, and nothing here is a recommendation.

What is NAD+ IV therapy (a NAD+ drip)?

NAD+ IV therapy, often called a NAD+ drip or infusion, is NAD+ given through a cannula into a vein over a period of time rather than by mouth or by a single needle dose.

NAD+ is a coenzyme found in cells, as our guide to what NAD+ is explains ¹.

In our dataset of 92 verified UK providers, 78 (85 per cent) list an IV route: 67 list IV only and 11 list both IV and injection ².

That is why we give IV therapy equal weight to NAD+ injections, which 23 of the 92 list ².

“Verified” means we read each provider’s own page on 11 November 2026; the dataset is not a complete register of UK providers.

How does a NAD+ drip differ from a NAD+ injection?

A drip runs into a vein through a cannula over a longer session, while an injection is a needle dose into a muscle or just under the skin.

	NAD+ IV drip	NAD+ injection (IM or SC)
Route	Into a vein through a cannula	Into a muscle or under the skin
Who may give it	If the product is a prescription-only medicine, an appropriate practitioner or someone acting on their directions ³	The same rule applies to any parenteral route ³
Session length as published by clinics	45 to 120 minutes in the three listings that state one (see below) ²	Not recorded in our data
Listed by (of 92 providers)	78 ²	23 ²
Single-session price, median, as displayed on clinic websites on 11 November 2026	£300 (n = 36 price points, 22 providers) ²	£90 (n = 10 price points, 10 providers) ²
Human outcomes trials found	None for ageing or wellness ⁴	None for IM ⁴; none for SC in our searches

We never pool IV and injection prices, because the products and doses differ.

What do clinics say a session involves?

Our dataset records route, dose, price and (for a few listings) session length, but not each clinic’s account of what happens during a session, so this section reports what we recorded and what independent sources describe.

Of the 78 IV listings, 68 are fixed clinics, 4 are mobile only and 6 offer both a clinic and mobile visits ².

Three listings state a session length in the price text we recorded: 45 minutes for 250 mg and 90 minutes for 500 mg, 2 hours, and 1 to 2 hours ².

A 2026 review notes, as anecdotal, that practitioners in wellness clinics often prefer slow infusions of 2 to 4 hours because rapid infusion can cause discomfort, flushing or nausea ⁵.

In a retrospective review of one commercial clinic, NAD+ infusions took longer than infusions of nicotinamide riboside (a mean of 97 minutes against 37 minutes) ⁶.

Because a drip uses a cannula, it is worth asking who inserts it, how fast the infusion runs, who monitors you and what happens if you feel unwell; there is a fuller list of questions at the end of this page.

What doses and session lengths do UK clinics list?

Most dose labels in the IV prices we recorded are 250 mg or 500 mg, and clinics’ labels are not evidence of what works.

This table covers the 36 single-session IV price points we recorded (22 providers), as displayed on clinic websites on 11 November 2026.

Dose label on the page	Price points	Providers	Lowest	Median	Highest
250 mg	14	14	£199	£284.50	£450
500 mg	15	15	£299	£380	£500
Other dose label (100 mg)	2	2	£150 and £270 (fewer than 3 points, so no statistic)	-	-
Dose not stated or ambiguous	5	-	£179, £250, £350, £400, £480 (raw points)	-	-

Across all 36 points the range is £150 to £500 and the median is £300 ².

Three IV course prices were recorded and kept out of these figures ².

Our guide to the published prices has the full breakdown.

For comparison, the human studies we found used different regimens from most clinic labels:

A pilot in 11 healthy men gave 750 mg of NAD+ over 6 hours ⁷.
A retrospective review of a commercial clinic described 500 mg on four consecutive days with 30-day follow-up (NAD+, n = 6) ^6, 5.
A 2026 review describes an earlier small uncontrolled study of 1,000 mg a day for 6 days (n = 8), which we did not read in the original ⁵.

These are descriptions of what was studied, not suggestions about what to have.

What does the evidence say about IV NAD+?

The evidence is thin: a 2026 systematic review found no outcomes trials of intravenous or intramuscular NAD+ for ageing or wellness ⁴.

The same review treated the one IV NAD+ pharmacokinetic pilot as “contextual evidence only” ⁴.

A 2026 narrative review says human evidence is “sparse and consists primarily of small uncontrolled studies, observational investigations, and isolated case reports” ⁸.

Its conclusion is that “current evidence regarding IV NAD+ therapy remains preliminary and insufficient to support routine clinical or wellness use” ⁸.

The pilot in 11 healthy men (8 received NAD+, 3 saline) measured blood and urine chemistry, not symptoms or health outcomes ⁷.

In it, NAD+ was rapidly and completely removed from plasma for at least the first two hours at 3 micromol per minute, which tells you about where it goes, not about any benefit ⁹.

A retrospective record review compared IV NAD+ (n = 6) with IV nicotinamide riboside (n = 8) in a commercial clinic, with no control group ⁶.

Two registered trials involving injected NAD+ or a related product have no results yet: NCT06919328 (injected nicotinamide riboside, injected NAD+ and placebo in healthy adults, recruiting) and NCT07328100 (a planned pilot of “Coenzyme I for Injection” against saline, not yet recruiting) ^10, 11.

UK advertising regulators have also looked at this area.

In April 2020 the ASA upheld a complaint about Instagram posts promoting a 250 mg NAD+ IV drip, finding they implied medicinal claims for an unlicensed product (ruling A20-1059547) ¹².

On 20 December 2023 the ASA published three rulings on IV vitamin drip providers, none mentioning NAD+, telling them not to claim health benefits until they held adequate evidence in normally healthy people ^{13, 14, 15}.

Our guide to the UK legal status explains how NAD+ is regulated.

What risks are specific to intravenous administration?

Reported short-term effects of IV NAD+ include nausea, abdominal discomfort, flushing, cramping and chest pressure, particularly at faster infusion rates, and long-term safety is not known ^8, 5.

A 2026 review summarises those effects from a handful of small studies, with no incidence rates available ⁵.

In the retrospective review of one commercial clinic, people given IV NAD+ (n = 6) reported moderate to severe gastrointestinal symptoms, increased heart rate and chest pressure during infusions, and the symptoms resolved when the infusion finished ⁶.

In the healthy-men pilot, which used a slow 6-hour infusion in 8 treated men, no adverse events were observed ⁷.

That tells you little about shorter clinic infusions.

A 2026 review states that long-term safety data are lacking ⁸.

It also raises a theoretical concern about NAD+ and cell-proliferation biology, citing no human evidence of harm, which should be read as “not known” rather than as a finding ⁵.

Any cannula carries general risks: an NHS trust patient leaflet says a cannula can lead to infections and names phlebitis (an inflamed vein, with swelling and redness) as the most common complication ¹⁶.

That leaflet is about cannulas in general, not NAD+.

Our guide to side effects and safety covers this in more depth.

How do I check a clinic that lists NAD+ IV?

Ask who prescribes and who inserts the cannula, what the product is, which regulator registers the clinic and how you will be monitored, then check the registration on the regulator’s own register.

Our guide on how to choose a clinic goes through each step.

Our own CQC check is a useful reference point: of the 78 IV-route providers, 38 matched a CQC-registered location, 5 matched a provider but not the clinic’s own address and 35 were not found ¹⁷.

Not every listed clinic is CQC-registered, and “not found” does not prove a clinic is unregistered.

CQC registration also does not mean the NAD+ service itself is regulated: CQC found in 2018 that an IV and IM vitamin clinic’s wellbeing-only services were outside its scope of registration ¹⁸.

CQC’s guidance says the “Treatment of disease, disorder or injury” activity does not include interventions carried out purely for cosmetic purposes ¹⁹.

In Wales, nurse-led clinics may fall outside Healthcare Inspectorate Wales registration, because services by health professionals not registered with the General Medical Council do not usually need it unless a listed service is provided ²⁰.

These are the questions most worth asking a clinic:

Who is the prescriber, what is their professional registration, and have they assessed my medical history? The NMC says prescribers need enough knowledge of your health and your full medical and prescribing history ²¹.
Is there a prescription or Patient Specific Direction for me, rather than a stock supply? ²¹
Who will insert the cannula, and what is their registration? ³
What is the product, who supplies it and is it a licensed medicine, an unlicensed “special” or an import? ²²
How fast will the infusion run, how long will it take and who monitors me? ⁵
What do I do if I feel flushing, nausea, cramps, chest pressure or a racing heart? ⁶
What human evidence do you rely on for my goal, and is it from trials of IV NAD+ specifically? ⁴
What is known about long-term safety, and will you say in writing that it is not known? ⁸
Can I take independent medical advice first, for example from my GP? ²³

You can compare clinics that list NAD+ IV by area, route and any published price, and then use the questions above.

This page is general information, not medical advice. Speak to your GP or a registered prescriber before deciding anything about NAD+ IV therapy, and read our medical disclaimer.

It was drafted with AI assistance from a fact-pack of primary sources by the NAD Injections editorial team and has not been clinically reviewed.

What is NAD+ IV therapy?